Capital Fund Management S.A. Supernus Pharmaceuticals, Inc. Transaction History

Capital Fund Management S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 12, 2019	SELL	$29.96 - $38.87 $6.8 Million - $8.83 Million	-227,078 Closed	0 $0
Q1 2019 May 13, 2019	SELL	$32.77 - $41.99 $2.48 Million - $3.17 Million	-75,577 Reduced 24.97%	227,078 $7.96 Million
Q4 2018 Feb 13, 2019	BUY	$30.84 - $49.51 $2.11 Million - $3.39 Million	68,478 Added 29.24%	302,655 $10.1 Million
Q3 2018 Nov 14, 2018	SELL	$42.7 - $56.55 $908,869 - $1.2 Million	-21,285 Reduced 8.33%	234,177 $11.8 Million
Q2 2018 Aug 14, 2018	BUY	$44.1 - $59.85 $5.78 Million - $7.84 Million	131,060 Added 105.35%	255,462 $15.3 Million
Q1 2018 May 15, 2018	BUY	$37.15 - $46.9 $1.25 Million - $1.57 Million	33,536 Added 36.91%	124,402 $5.7 Million
Q4 2017 Feb 09, 2018	BUY	$36.4 - $42.6 $3.31 Million - $3.87 Million	90,866	90,866 $3.62 Million

290

60.7M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.05B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.